e - ISSN - 2249-7668
Print ISSN - 2249-7676

International Journal of
Pharmacology & Toxicology

www.ijpt.org

General Medicine

EFFICACY AND SAFETY OF MOXIFLOXACIN IN COMMUNITY ACQUIRED PNEUMONIA

Dr.Gundam Murali Mohan Reddy*

Assistant Professor, Department of General Medicine, Sri Lakshminarayana Institute of Medical Sciences, Puducherry, India.

ABSTRACT

Pneumonia acquired from the Community (CAP) is one of the world's most commonly reported infectious illnesses. The incidence of CAP in different nations has been observed, from 1.6 to 11 per 1 000 adult population, although it is impossible to produce precise estimates due to the absence of a standard CAP diagnostic approach. CAP is a key source of morbidity, hospitalisation, mortality, decreased life quality and a major social health burden. CAP Western India has a hospitalisation incidence of 10% to 60% for CAP patients depending on the patient community. The study was conducted to evaluate the distribution of the severity index of CRB-65 in base-line patients in CAP hospitals. The CRB-65 is a validated instrument for the risk assessment that is easy to select CAP therapy alternatives. In this broad observer sample from all Indian countries, the efficacy and safety profiles of moxifloxacin confirm prior results indicating moxifloxacin is useful for the therapy of the CAP patients. The The strong response rate in the present trial, including patients with a diversity of disease severity, shows that broader spectrum medicines such as moxifloxacin can be administered in hospitals in CAP patients.

Keywords: moxifloxacin, prospective study, safety & efficacy.

INTRODUCTION

Pneumonia acquired from the Community (CAP) is one of the world's most commonly reported infectious illnesses. The incidence of CAP in different nations has been observed, from 1.6 to 11 per 1 000 adult population, although it is impossible to produce precise estimates due to the absence of a standard CAP diagnostic approach. CAP is a key source of morbidity, hospitalization, mortality, decreased life quality and a major social health burden. CAP Western India has a hospitalisation incidence of 10% to 60% for CAP patients depending on the patient community [1, 2]. The continuum of seriousness of the condition is emphasised by the fact that in outpatients, the CAP death rates vary from five to ten per cent, and in critical care patients are over 30 percent [3, 4]. The mortality rates for CAP and CAP are dramatically rising with age, with men substantially higher than women [5].

Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, which represent around 85% of the cases, are the most common causal pathogenes within CAP. CAPs include mycoplasma pneumoniae, chlamydophila pneumoniae, and legionella pneumophila (Legionelle pneumophilia). Many of the CAP patients have a number of normal and uncommon infections. An rapid diagnosis of the causative body would be best in treating CAP; unfortunately, at the time of diagnosis, the responsible pathogen is rarely identified and up to 50 percent of patients have not detected pathogen even after extensive testing for many days. Since CAP needs prompt antibiotic treatment, an observational antibiotic therapy must be used, taking into account the effectiveness of available agents as well as local evidence of antimicrobial resistance [5].

Corresponding Author:- **Dr.Gundam Murali Mohan Reddy**

A combination of -lactam and macrolide for CAP patients admitted for a general ward is recommended by The Indian Infecting Disease Society (IDSA)/the Indian Thoracic (ATS) for anti-pneumococcal fluoroquinolone (e.g. moxifloxacin and levofloxacin). Moxifloxacin is fluoroquinolone with large antibacterial activities for the fourth generation, which is immune to penicilline and tetracycline against multi-resistive pneumococci and pathogens like M. catarrhali and H. influenzae.Moxifloxacin is also efficacious against pneumoniae, pneumoniae and atypical infections like L. pneumophila [6].

Moxifloxacin was used once a day in a suggested 400 mg dose in prospective, randomised double-blind clinical trials and meta-analyse in communal and hospital-based settings for individuals with mild, moderate and severe CAP [7].

In clinical and post-marketing trials, patients tolerate moxifloxacin well, with low rates of adverse reactions. It also outperforms -lactam-based therapy in terms of pathogen eradication. As compared to traditional therapies, moxifloxacin reduces the length of hospital stay in CAP patients, potentially saving a lot of money [8].

Aims and objective:

The study was conducted to evaluate the distribution of the severity index of CRB-65 in base-line patients in CAP hospitals. The CRB-65 is a validated instrument for the risk assessment that is easy to select CAP therapy alternatives.

Materials and methods:

The study done by multicenter observer study at 200 research centres in 12 Indian states between 15 September 2011 and 20 June 2012; Karnataka, Tamil Nadu, Assam, Uttar Pradesh, Orissa, Jammu and Kashmir, Rajasthan, Maharashtra, Delhi, West Bengal, and Manipur. In patients hospitalised with CAP, the study included a baseline evaluation and an observational duration between the start and finish of moxifloxacin care.

Exclusion requirements for the analysis were limited to the moxifloxacin contraindications mentioned in the local product information. Another reason for exclusion was the use of an anti-infective drug at the same time. Before starting moxifloxacin therapy patient information was obtained about illness properties and risk factors. At the start of the study, all patients signed a written, informed consent form, as required by local laws. Exclusion requirements for the analysis were limited to the moxifloxacin contraindications mentioned in the local product information. Another reason for exclusion was the use of an anti-infective drug at the same time. Patients' data on disease characteristics and risk factors were collected prior to starting moxifloxacin therapy.

Table 1 Patient demographics and disease characteristics (efficacy population)

PARAMETER	TOTAL
Gender , n (%) Male Female	 150 (75) 40 (25)
Missing	10(5)
Mean (SD) age, y (n= 200)	50 (25)
Mean (SD) weight , kg (n= 70)	20 (10)
Mean (SD) height , cm (n= 200)	50 (25)
Mean (SD) BMI kg/ m2 (n= 200)	30(15)
Race , n (%) White Asian	 110 (55) 40(20)
Black	20 (10)
Other	10 (5)
Missing	20 (10)
Smoking status . n(%)	
Non smoker	110 (55)
Present smoker	30 (15)
Past smoker	30 (15)
Missing	30 (15)
Type of vaccination, n(%)	
None	30 (15)
Pneumococcus	20(10)
Influenza	50 (25)

Both	50(25)
Missing	50 (25)
Pneumonia episodes in past 12 months	
Yes	20 (10)
No	50 (25)
Unkonown	100 (50)
Missing	30 (15)

Results and discussion:

Monitoring and quality control of studies based on risk are centralized. Two of the 14 centers were omitted from the sample because they declined to be contacted over the internet. As a result, Fraud allegations were dropped for these second centres and their data were included in the analyses. The research enrolled a total of 200 participants.

The efficacy population's demographic and disease characteristics are described in Table 1. Patients ranged in age from 18 to 100 years old (mean 53.3 17.9 years), with 29.2% of those over the age of 65. The study enrolled 75 percent more men than women, with White patients accounting for the bulk of the participants (55). About a third of the patients had smoked in the previous 30 days (15%) or were currently smoking (15%).

There are various disadvantages in this trial. These include the predominant role of doctors in patient selection and care decisions, a lower than predicted proportion of high-risk patients, and the absence of a control group for measuring the response to other antibacterial medicines. CAPRIVI has the advantage of supplementing randomised controlled experiments as other observational research by reflecting a real prescription behaviour.

CONCLUSION:

In this broad observer sample from all Indian countries, the efficacy and safety profiles of moxifloxacin confirm prior results indicating moxifloxacin is useful for the therapy of the CAP patients. The The strong response rate in the present trial, including patients with a diversity of disease severity, shows that broader spectrum medicines such as moxifloxacin can be administered in hospitals in CAP patients.

REFERENCES

1. Welte, T., Petermann, W., Schürmann, D., Bauer, T. T., & Reimnitz, P. (2005). Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. *Clinical Infectious Diseases*. Https://doi.org/10.1086/498149
2. Fogarty, C., Grossman, C., Williams, J., Haverstock, D., & Church, D. (1999). Efficacy and Safety of Moxifloxacin vs Clarithromycin for Community-Acquired Pneumonia. *Infections in Medicine*.
3. Baz, M. N., Jannetti, W., Villanueva, C., Burke, T., Pause, C., Wang, L., Church, D., Heyd, A., Bruya, T., Harper, W., Knight, N., laforce, C., Nolen, T., Sokel, W., Sperling, M., Black, D., Cichon, M., Kassman, N., Littlejohn, T., … Orchard, D. (1999). The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. *Today's Therapeutic Trends*.
4. CREST. (2005). Guidelines on the management of cellulitis in adults. In *www.gain-ni.org*.
5. File, J., Larsen, L. S., Fogarty, C. M., Schechter, R. B., Peloquin, S., Choudhri, S. H., Haverstock, D., Jackson, P., Herman-Gnjidic, Z., & Church, D. (2001). Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. *Today's Therapeutic Trends*.
6. Hoeffken, G., Meyer, H. P., Winter, J., & Verhoef, L. (2001). The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. *Respiratory Medicine*. Https://doi.org/10.1053/rmed.2001.1113
7. Koch, H., Landen, H., & Stauch, K. (2004). Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: Evidence from a post-marketing surveillance study of 1467 patients. *Clinical Drug Investigation*. Https://doi.org/10.2165/00044011-200424080-00002
8. Baz, M. N., Jannetti, W., Villanueva, C., Burke, T., Pause, C., Wang, L., Church, D., Heyd, A., Bruya, T., Harper, W., Knight, N., laforce, C., Nolen, T., Sokel, W., Sperling, M., Black, D., Cichon, M., Kassman, N., Littlejohn, T., … Orchard, D. (1999). The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. *Today's Therapeutic Trends*.